Please assess the completion status of the following clinical trial:

Trial Title: Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed adenocarcinoma of the rectum that begins within 15cm of the anal verge as determined by sigmoidoscopy and/or colonoscopy, with no evidence of distant metastatic disease. A complete colonoscopy to the cecum is recommended prior to initiating protocol therapy.~* Staging with transrectal ultrasound or endorectal coil Magnetic resonance imaging (MRI) to confirm clinical stage of T3 or T4 or lymph node positive rectal adenocarcinoma~* Tumor is K-ras wildtype by method of choice at respective institution (testing codons 12 and 13)~* Performance status: Eastern Cooperative Oncology Group Performance Score (ECOG PS) less than or equal to 2~* 18 years of age or older~* No evidence of metastatic disease by abdominal/pelvic (Computed tomography) CT and chest imaging~* Adequate bone marrow, renal,and hepatic function as outlined in protocol~* All patients will be evaluated by a surgeon and considered a candidate for definitive surgery~* Coumadin or heparin management for line care of other indications is permitted. The International Normalised Ratio (INR) will be monitored weekly in patients taking coumadin.~Exclusion Criteria:~* Prior treatment for this malignancy~* Prior history of pelvic radiation therapy~* Prior history of 5-FU based or EGFR receptor inhibitor therapy~* Prior history of an allergic reaction to a monoclonal antibody~* Uncontrolled serious medical or psychiatric illness~* Significant history of uncontrolled cardiac disease~* Sexually active women of childbearing potential must use an effective method of birth control during the course of the study~* Unwilling to agree to pre and post-cetuximab sigmoidoscopy and biopsy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cetuximab, 5-FU and Radiation (Type: EXPERIMENTAL): Cetuximab: Participants first receive cetuximab at the initial dose of 400 mg/m2 intravenously (IV) administered over 120 minutes, followed by weekly infusions at 250 mg/m2 over 60 minutes. Cetuximab is given as single agent during the first 3 weeks on study and then in combination with 5-FU and radiation.~Radiation: Radiation therapy given as standard of care is initiated after the 3rd dose of cetuximab with a total dose of 50.4 Gray (Gy) in 28 fractions over approximately 5.5 weeks.~5-FU: Participants receive 5-Fluorouracil (5-FU) continuous infusion through central venous access at 225 mg/m2/day given 7 days a week starting day 1 of radiation (no later than 3 days) and lasting the duration of radiation therapy.~Duration of neoadjuvant therapy is estimated to be 9 weeks. Surgery follows at week 13-17. Sigmoidoscopy is performed for biopsy prior to the 1st dose and after 3rd dose of cetuximab before the initiation of radiation and/or 5-FU.

Based on this trial design, predict the completion outcome and termination type (if applicable).